Results 81 to 90 of about 77,203 (291)
A quick review of carbamazepine pharmacokinetics in epilepsy from 1953 to 2012
Background: Carbamazepine has been used as AEDs since 1965, and is most effective against partial seizures. Two basic mechanisms of action have been proposed: 1) enhancement of sodium channel inactivation by reducing high-frequency repetitive firing of ...
Zahra Tolou-Ghamari +3 more
doaj
Cognitive Effects of Carbamazepine and Phenytoin: Reanalysis [PDF]
J Gordon Millichap
openalex +1 more source
Abstract Objective Artificial intelligence (AI)‐powered chatbots are increasingly used for patient education and mental health support, yet their effectiveness in epilepsy care remains underexplored. This study examines text‐based interactions between users and EpiloBot, an epilepsy‐focused chatbot, to understand conversational patterns and emotional ...
Keiichi Watanuki +10 more
wiley +1 more source
An 18-year-old woman presented to the emergency department. She had ingested 43 extended-release tablets of carbamazepine 400 mg. Although the patient had high carbamazepine plasma levels and classified as severe intoxication, her clinical symptoms were ...
Heshu Abdullah-Koolmees +4 more
doaj +1 more source
Objective: To investigate the protective effect of purslane with carbamazepine treatment. Methods: Male albino rats were modulated by pilocarpine to be epileptic.
Widad Makhdour Al-Bishri +2 more
doaj +1 more source
Influence of astemizole, an H1 receptor antagonist, on the locomotors activity of carbamazepine and valproate in mice [PDF]
Mariusz Świąder, Katarzyna Świąder
openalex +1 more source
Therapeutic drug monitoring and methods of quantitation for carbamazepine
Carbamazepine is an early anticonvulsant still used today in the treatment of several forms of epilepsy. An active metabolite in the human body contributes to its pharmacological effect.
Cristian Tuchila +6 more
doaj +1 more source
Stiripentol use in Dravet syndrome patients in the USA: Results of a real‐world study
Abstract Objective Dravet syndrome (DS) is a severe developmental and epileptic encephalopathy with a high seizure burden and mortality risk. Stiripentol, one of the first DS‐specific therapies, received FDA approval in 2018 but its real‐world use and impact post‐approval in the USA remain insufficiently characterized.
Elaine Wirrell +11 more
wiley +1 more source
Association between SCN1A polymorphism and carbamazepine‐resistant epilepsy [PDF]
Tomohide Abe +5 more
openalex +1 more source
Abstract Objective Variants in KCNQ2 encoding the voltage‐gated potassium channel KV7.2 are associated with developmental and epileptic encephalopathy (DEE) of varying severity. This study examined the relationship of KCNQ2 variant dysfunction with the neurodevelopmental phenotype of individuals with KCNQ2‐DEE. Methods A parent‐reported survey gathered
Jessa S. Bidwell +4 more
wiley +1 more source

